|
Breast Carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of ER, CD34 and p53 in breast cancer tissue can be evaluated by color Doppler ultrasonographic features, which is conducive to assessing the prognosis of these patients.
|
29745079 |
2019 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Statistical analysis of epithelial cytoplasmic expression revealed association of MFAP5 expression with tumor size (P=0.046), high histologic grade (P=0.007), presence of lymph node metastasis (P=0.014), poor Nottingham Prognostic Index (NPI) (P=0.001), late stage (P=0.008), immunohistochemical subtypes of BC (P=0.018), and increased microvessel density using CD34 immunostianing (P=0.04).
|
30320661 |
2019 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
This study aims to investigate the correlations between the expression of human epidermal growth factor receptor 2 (C-erB-2), CD34, and estrogen receptor (ER) in breast cancer (BC) patients, and the signs of conventional ultrasonography and ultrasound elastography.
|
30229826 |
2018 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We examined vascular proliferation using double immunohistochemistry (CD34/Ki67) in a series of 54 invasive breast carcinomas and compared the results with standard MVD, molecular subtypes and other classical parameters.
|
29275302 |
2018 |
|
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Association analysis identifies 65 new breast cancer risk loci.
|
29059683 |
2017 |
|
Breast Carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The average density of FSHR+ and CD34+ blood vessels as well as of D2-40+ lymphatic vessels did not differ significantly among breast cancer subgroups.FSHR+ vessels did not express VEGFR2.
|
25652007 |
2015 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry staining for CCL18 and CD34 was performed on 179 cases, including 29 normal cases as control, 47 cases with benign breast diseases, and 103 cases with breast cancer.
|
26294068 |
2015 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry confirmed that CDK11(p58) was negatively associated with angiogenesis-related proteins such as VEGF, CD31 and CD34 in breast cancer patients.
|
26470709 |
2015 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), delivered as a membrane-bound molecule expressed on the surface of adenovirus-transduced CD34(+) cells (CD34-TRAIL(+)), was analyzed for its apoptotic activity in vitro on 12 breast cancer cell lines representing estrogen receptor-positive, HER2(+) and triple-negative (TN) subtypes and for its effect on tumor growth, vascularization, necrosis, and lung metastasis incidence in NOD/SCID mice xenografted with the TN breast cancer line MDA-MB-231.
|
23053664 |
2012 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical staining with D2-40 and CD34 was performed on formalin-fixed, paraffin-embedded tissue sections of 254 invasive breast tumors of 247 patients with node negative and node positive early breast cancer.
|
18165897 |
2008 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Human CD34(+) cells spiked with breast cancer cells were infected with an adenoviral vector encoding the cytosine deaminase transgene (Ad-CMV-CD).
|
12208755 |
2002 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
To test this hypothesis, the breast cancer cell lines T47D and MCF-7 were infected with a recombinant AAV-2 vector expressing the green fluorescent protein (GFP) gene; in addition, human CD34+ mobilized peripheral progenitor cells were infected with the same vector.
|
10811478 |
2000 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We describe a new technique for purging breast cancer cells (BCCs) that combines two independent strategies: (a) the specific enrichment of CD34+ progenitor stem cells by magnetic antibody cell separation (MACS), and then (b) infection of the contaminating BCCs with a recombinant adGAL-TEK marker/suicide gene adenovirus (ad-v), followed by the addition of ganciclovir (GCV).
|
10389945 |
1999 |
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We studied the efficiency of indirect tumor cell purging via enrichment of CD34+ hematopoietic progenitor cells from leukapheresis products (LP) in breast cancer patients based on immunomagnetic selection of CD34+ cells.
|
8978310 |
1997 |